• Akron Biotech, Octapharma enter Human AB Serum global production deal pharmaceutical-technology
    January 22, 2021
    Akron Biotech has signed an exclusive global agreement with Switzerland-based Octapharma to produce virally inactivated Human AB Serum for the cell therapy market using the latter’s Octaplas.
  • Fresenius Terminates $4.3-Billion Merger with Akron americanpharmaceuticalreview
    May 18, 2018
    Fresenius Kabi has decided to terminate the company’s previously announced merger agreement with Akorn, a United States-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.
PharmaSources Customer Service